Scarica l'app Stockscreener
1.93
5.85%
-0.12
Pre-mercato:
1.99
0.06
+3.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.05
Aprire:
$2.01
Volume 24 ore:
386.81K
Relative Volume:
0.38
Capitalizzazione di mercato:
$69.67M
Reddito:
$832.00K
Utile/perdita netta:
$-135.12M
Rapporto P/E:
-0.3169
EPS:
-6.09
Flusso di cassa netto:
$-124.69M
1 W Prestazione:
-1.53%
1M Prestazione:
-9.39%
6M Prestazione:
-71.66%
1 anno Prestazione:
-82.84%
Intervallo 1D:
$1.91
$2.07
Intervallo di 1 settimana:
$1.88
$2.075
Portata 52W:
$1.74
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Nome
Inovio Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 410-3134
Indirizzo
6769 MESA RIDGE RD., SAN DIEGO, PA
Confronta INO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.93 | 69.67M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-01-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Downgrade | Maxim Group | Buy → Hold |
| 2022-11-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Ripresa | Jefferies | Hold |
| 2021-09-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Iniziato | Jefferies | Hold |
| 2021-03-23 | Iniziato | BofA Securities | Neutral |
| 2021-02-12 | Iniziato | Oppenheimer | Outperform |
| 2020-11-17 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Aggiornamento | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-01 | Downgrade | Maxim Group | Buy → Hold |
| 2020-07-01 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Downgrade | Stifel | Buy → Hold |
| 2020-05-21 | Iniziato | The Benchmark Company | Buy |
| 2020-04-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Iniziato | ROTH Capital | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
| 2017-10-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Iniziato | Citigroup | Buy |
| 2017-06-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Reiterato | Maxim Group | Buy |
| 2017-03-16 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-03-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mostra tutto
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19 - Marketscreener.com
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 - BioSpace
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO Earnings Alert: Key Q4 and 2024 Financial Results Coming March 18What to Watch - StockTitan
Recurrent Respiratory Papillomatosis Market Set to Grow - openPR
Inovio Pharmaceuticals : to start global late-stage COVID-19 vaccine trial this summer -May 10, 2021 at 06:41 pm EDT - Marketscreener.com
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Anus Neoplasms Treatment Market Size Report 2032 | Inovio - openPR
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $12.40 - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cervical Dysplasia Market to Show Remarkable Growth Trends from - openPR
Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Inovio Investor Alert: Class Action Lawsuit Filed - ACCESS Newswire
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis - MyChesCo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Inovio Pharmaceuticals (INO) Investors with $100K Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud - ACCESS Newswire
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INO-3107 shows promise in reducing surgeries for RRP patients By Investing.com - Investing.com Canada
INOVIO Advances INO-3107 Into BLA Submission After Positive Phase 1/2 Trial Results For RRP - Nasdaq
INOVIO Announces Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as A Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - Marketscreener.com
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
INO-3107 shows promise in reducing surgeries for RRP patients - Investing.com India
Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications - Marketscreener.com
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - PR Newswire
Zika Vaccines Market Poised for Breakthrough Growth by 2032 | Rising Demand & Key Innovations: Sanofi S.A, - EIN News
Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference - Marketscreener.com
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference - Quantisnow
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc Azioni (INO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):